The technology uses proprietary formulations which are based on ionic minerals and ionic salts. The theory of the inventors is that these formulations target cells which do not follow the full Krebs (aerobic) metabolic cycle, such as most cancer cells as well as pathogens like viruses, bacteria, and fungi. They believe that these anaerobic cells receive a toxic metal overdose while healthy cells, which follow the full Krebs cycle, absorb only the minerals that they need and expel what they do not need. The unique IBAL system uses ammine, hydrogen, sulfur, and water in a unique manufacturing process to create hexaaqua metals. The first ionic formulation, ION-ZC1, uses zinc and copper cations, a second ION-ZCM1, uses zinc, copper, and magnesium cations. Other ionic metal combinations are currently being developed such as IBAL-ZCMMS in the pipeline for injectable oncology research.
Recent clinical testing supports these claims. Intravenous and topical testing of ION-ZC1 on mice with melanoma resulted in markedly slower tumor growth than control groups. Highly diluted ION-ZC1 also inhibited the growth of a dozen bacteria and fungi, including antibiotic-resistant MRSA. Ion Gel ZCM-25® has been tested on multiple bacterial strains, fungus, and the SARS-CoV-2 virus with extremely high kill rates.